ArcticZymes Technologies is attending MEDICA 2022

ArcticZymes Technologies is attending the MEDICA 2022 at the Messe Düsseldorf, Germany from 14-17 November. Kees Linschooten, Senior Business Development Manager, Helge Lind, Ph.D., Senior Market Development Manager, and Dirk Hahneiser VP of Business Development and Marketing are looking forward to meeting you at the Diagnostic Hall 3, booth # J26 for a discussion on our enzyme solutions for sensitive, …

Q3 and first 9 months 2022 results

Tromsø, Norway, 27th October 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 29.3 million (25.2) and an EBITDA of NOK 2.8 million (9.9) for the third quarter of 2022. Highlights from Q3 and first 9 months 2022 ArcticZymes Technologies (AZT) had Q3 sales of NOK 29.3 million growing by 16% (Q3 2021: NOK 25.2 million) and sales for …

M-SAN HQ in Lentivirus Purification Poster Presented at 29th ESGCT

Our collaborators at University College London (UCL) Biochemical Engineering Department have presented a poster on the use of M-SAN HQ for purification of lentivirus vectors for cell therapy applications. The poster entitled: “Removal of contaminating DNA in downstream processing of lentiviral vectors” was presented at the 29th Annual European Society for Cell and Gene Therapy at the EICC in Edinburgh, …